Faculty Profiles - KANDA Mitsuro

Papers - KANDA Mitsuro

Division display 161 - 180 of about 573 ／ All the affair displays >>

十二指腸肉腫の1例 Reviewed

山中雅也, 高見秀樹, 園原史訓, 猪川祥邦, 林真路, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本臨床外科学会雑誌 Vol. 82 ( 5 ) page： 1023 - 1023 2021.5

Transcriptomic Profiling Identifies a Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer. Reviewed International journal

In-Seob Lee, Heonyi Lee, Hoon Hur, Mitsuro Kanda, Jeong-Hwan Yook, Byung-Sik Kim, Yanghee Woo, Yasuhiro Kodera, Kwangsoo Kim, Ajay Goel

Clinical cancer research : an official journal of the American Association for Cancer Research Vol. 27 ( 8 ) page： 2292 - 2300 2021.4

Language：Japanese Publishing type：Research paper (scientific journal)

PURPOSE: Gastric cancer peritoneal carcinomatosis is fatal. Delay in detection of peritoneal metastases contributes to high mortality, highlighting the need to develop biomarkers that can help identify patients at high risk for peritoneal recurrence or metastasis. EXPERIMENTAL DESIGN: We performed a systematic discovery and validation for the identification of peritoneal recurrence prediction and peritoneal metastasis detection biomarkers by analyzing expression profiling datasets from 249 patients with gastric cancer, followed by analysis of 426 patients from three cohorts for clinical validation. RESULTS: Genome-wide expression profiling identified a 12-gene panel for robust prediction of peritoneal recurrence in patients with gastric cancer (AUC = 0.95), which was successfully validated in a second dataset (AUC = 0.86). Examination of 216 specimens from a training cohort allowed us to establish a six gene-based risk-prediction model [AUC = 0.72; 95% confidence interval (CI): 0.66-0.78], which was subsequently validated in an independent cohort of 111 patients with gastric cancer (AUC = 0.76; 95% CI: 0.67-0.83). In both cohorts, combining tumor morphology and depth of invasion further improved the predictive accuracy of the prediction model (AUC = 0.84). Thereafter, we evaluated the performance of the identical six-gene panel for its ability to detect peritoneal metastasis by analyzing 210 gastric cancer specimens (prior 111 patients plus additional 99 cases), which discriminated patients with and without peritoneal metastasis (AUC = 0.72). Finally, our biomarker panel was also remarkably effective for identifying peritoneal micrometastasis (AUC = 0.72), and its diagnostic accuracy was significantly enhanced when depth of invasion was included in the model (AUC = 0.85). CONCLUSIONS: Our novel transcriptomic signature for risk stratification and identification of high-risk patients with peritoneal carcinomatosis might serve as an important clinical decision making in patients with gastric cancer.

DOI： 10.1158/1078-0432.CCR-20-3835

Web of Science

PubMed

Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53-Bcl-2 intrinsic apoptosis pathway. Reviewed International journal

Takashi Miwa, Mitsuro Kanda, Dai Shimizu, Shinichi Umeda, Koichi Sawaki, Haruyoshi Tanaka, Chie Tanaka, Norifumi Hattori, Masamichi Hayashi, Suguru Yamada, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera

British journal of cancer Vol. 124 ( 8 ) page： 1449 - 1460 2021.4

Language：Japanese Publishing type：Research paper (scientific journal)

BACKGROUND: Gastric cancer (GC) with hepatic metastasis has a poor prognosis. Understanding the molecular mechanisms involved in hepatic metastasis may contribute to the development of sensitive diagnostic biomarkers and novel therapeutic strategies. METHODS: We performed transcriptome analysis of surgically resected specimens from patients with advanced GC. One of the genes identified as specifically associated with hepatic metastasis was selected for detailed analysis. GC cell lines with knockout of the candidate gene were evaluated in vitro and in vivo. Expression of the candidate gene was analysed in GC tissues from 300 patients. RESULTS: Ethanolamine kinase 2 (ETNK2) was differentially upregulated in GC patients with hepatic metastasis. ETNK2 expression was elevated in GC cell lines derived from haematogenous metastases. ETNK2 knockout significantly suppressed proliferation, invasion, and migration; increased apoptosis; reduced Bcl-2 protein expression; and increased phosphorylated p53 expression. In mouse xenograft models, ETNK2 knockout virtually abolished hepatic metastasis. Stratification of GC patients based on ETNK2 mRNA level revealed significant associations between high ETNK2 tumour expression and both hepatic recurrence and worse prognosis. CONCLUSIONS: Upregulation of ETNK2 in GC enhances hepatic metastasis, possibly via dysregulation of p53-Bcl-2-associated apoptosis. ETNK2 expression may serve as a biomarker for predicting hepatic recurrence and a therapeutic target.

DOI： 10.1038/s41416-021-01271-7

Web of Science

PubMed

Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Reviewed International journal

Masaya Suenaga, Tsutomu Fujii, Suguru Yamada, Masamichi Hayashi, Keiko Shinjo, Hideki Takami, Yukiko Niwa, Fuminori Sonohara, Dai Shimizu, Mitsuro Kanda, Daisuke Kobayashi, Chie Tanaka, Goro Nakayama, Masahiko Koike, Michitaka Fujiwara, Yutaka Kondo, Yasuhiro Kodera

Annals of surgical oncology Vol. 28 ( 4 ) page： 2277 - 2286 2021.4

Language：Japanese Publishing type：Research paper (scientific journal)

BACKGROUND: The clinical role of peritoneal lavage cytology (CY) in pancreatic ductal adenocarcinoma (PDAC) remains controversial, partly due to its low sensitivity. This study aimed to develop a new biomarker, defined as peritoneal lavage tumor DNA (ptDNA), using DNAs extracted from peritoneal lavage samples from patients with PDAC. METHODS: Samples were collected intraoperatively from 89 PDAC patients who underwent pancreatectomy between 2012 and 2017. Droplet digital polymerase chain reaction (PCR) was used to measure ptDNA for detection of KRAS mutations. The ptDNA status and clinical characteristics were retrospectively evaluated. RESULTS: Positive ptDNA was found in 41 patients, including all 9 patients positive for CY (CY+) and 32 patients negative for CY (CY-). The mutant allele frequency was significantly higher in the CY+ patients than in the CY- patients. The disease-free survival (DFS) and overall survival (OS) were significantly poorer in the high-ptDNA group than in the low-ptDNA group (median DFS, 11.0 vs. 18.8 months; p = 0.007; median OS, 28.7 vs not reached; p = 0.001). The survival curves of DFS and OS in the CY+ group were almost equal to those in the CY- and high-ptDNA group. In a multivariable analysis, ptDNA was an independent predictive factor for DFS (p = 0.025) and OS (p = 0.047). The estimated cumulative incidence of peritoneal recurrence was 45.5% in the high-ptDNA group. The ptDNA biomarker had a much higher sensitivity for peritoneal recurrence than CY, whereas CY had higher specificity. CONCLUSIONS: As a promising biomarker, ptDNA may predict poor prognosis and peritoneal recurrence in PDAC, resolving the controversy surrounding CY.

DOI： 10.1245/s10434-020-08990-w

Web of Science

PubMed

GAD1の食道扁平上皮癌根治的切除後予後予測バイオマーカーとしての意義 Reviewed

岸田貴喜, 神田光郎, 清水大, 田中千恵, 園原史訓, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： PS - 4 2021.4

胃癌における組織中RNFT2遺伝子発現と予後の関連性の検討 Reviewed

笹原正寛, 神田光郎, 清水大, 田中千恵, 園原史訓, 高見秀樹, 猪川祥邦, 服部憲史, 林真路, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： PS - 4 2021.4

肝胆膵領域癌におけるサルコペニアの臨床的意義と当教室の周術期対策 Reviewed

猪川祥邦, 山田豪, 横山幸浩, 薮崎紀充, 二宮豪, 田中伸孟, 園原史訓, 高見秀樹, 服部憲史, 林真路, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 3 2021.4

片側肝動脈合併切除を伴う膵頭十二指腸切除後の肝動脈血流の評価と早期合併症に関する検討 Reviewed

鈴木雄之典, 山田豪, 猪川祥邦, 田中伸孟, 園原史訓, 高見秀樹, 服部憲史, 林真路, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： PS - 1 2021.4

当教室における膵頭十二指腸切除術後出血に対する対策と治療効果の検討 Reviewed

田中伸孟, 山田豪, 園原史訓, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 4 2021.4

切除肝細胞癌におけるYTH domain family 2の臨床的意義 Reviewed

中川暢彦, 園原史訓, 田中克仁, 砂川祐輝, 猪川祥邦, 高見秀樹, 林真路, 山田豪, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 7 2021.4

パンデミック下における外科卒前教育の工夫 Reviewed

高見秀樹, 小池聖彦, 鈴木雄之典, 栗本景介, 田中伸孟, 柴田雅央, 園原史訓, 武内大, 猪川祥邦, 服部憲史, 林真路, 神田光郎, 田中知恵, 山田豪, 中山吾郎, 菊森豊根, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： SP - 7 2021.4

ゲノム編集技術を用いたLAMP5遺伝子の胃癌転移巣形成における役割の検討 Reviewed

梅田晋一, 神田光郎, 清水大, 田中千恵, 園原史訓, 高見秀樹, 猪川祥邦, 服部憲史, 林真路, 山田豪, 中山吾郎, 小池聖彦, Fujiwara Michitaka, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 5 2021.4

UR-M膵癌に対するconversion surgeryの課題 Reviewed

加藤吉康, 山田豪, 田中伸孟, 園原史訓, 高見秀樹, 猪川祥邦, 林真路, 服部憲史, 清水大, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 6 2021.4

胃癌に対する腹腔鏡下手術でのIndocyanine Green蛍光法を用いたマーキング法の成績 Reviewed

佐藤敏, 田中千恵, 園原史訓, 清水大, 高見秀樹, 猪川祥邦, 服部憲史, 林真路, 神田光郎, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： PS - 6 2021.4

食道扁平上皮癌術後長期生存例における多重癌発生状況 Reviewed

清水大, 小池聖彦, 神田光郎, 園原史訓, 高見秀樹, 猪川祥邦, 服部憲史, 林真路, 田中千恵, 山田豪, 中山吾郎, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 1 2021.4

膵癌における術前治療中の腫瘍マーカーの比較・検討 Reviewed

砂川祐輝, 山田豪, 田中伸孟, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： PS - 4 2021.4

膵癌におけるオリゴメタスタシスの臨床的意義 Reviewed

山中雅也, 山田豪, 林真路, 園原史訓, 猪川祥邦, 高見秀樹, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 5 2021.4

胃癌切除後予後と原発巣組織中CRABP1発現の相関性の検討 Reviewed

坂田和規, 神田光郎, 清水大, 園原史訓, 高見秀樹, 猪川祥邦, 服部憲史, 林真路, 田中千恵, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： PS - 5 2021.4

クローン病再手術症例に対する腹腔鏡手術の検討 Reviewed

服部憲史, 中山吾郎, 上原圭, 相場利貞, 佐藤雄介, 小倉淳司, 神田光郎, 田中千恵, 山田豪, 小池聖彦, 藤原道隆, 江畑智希, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 121回 page： PS - 2 2021.4

Genome-wide identification and characterization of circular RNA in resected hepatocellular carcinoma and background liver tissue. Reviewed International journal

Yuki Sunagawa, Suguru Yamada, Fuminori Sonohara, Keisuke Kurimoto, Nobutake Tanaka, Yunosuke Suzuki, Yoshikuni Inokawa, Hideki Takami, Masamichi Hayashi, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera

Scientific reports Vol. 11 ( 1 ) page： 6016 - 6016 2021.3

Language：Japanese Publishing type：Research paper (scientific journal)

Circular RNA (circRNA) is a type of non-coding RNA known to affect cancer-related micro RNAs and various transcription factors. circRNA has promise as a cancer-related biomarker because its circular structure affords high stability. We found using high-throughput sequencing that seven candidate circRNAs (hsa_circ_0041150, hsa_circ_0025624, hsa_circ_0001020, hsa_circ_0028129, hsa_circ_0008558, hsa_circ_0036683, hsa_circ_0058087) were downregulated in HCC. The expression of these circRNAs was examined by quantitative PCR in 233 sets of HCC and matched background normal liver tissues, and correlations between candidate circRNA expression and prognosis were evaluated. The results of quantitative PCR showed that expression of hsa_circ_0041150, hsa_circ_0001020 and hsa_circ_0008558 was significantly lower in HCC than in background normal liver tissues. Kaplan-Meier analysis revealed that low expression of hsa_circ_0001020, hsa_circ_0036683, and hsa_circ_0058087 was associated with poor recurrence-free (RFS) and overall survival (OS) in HCC. Additionally, multivariate analysis revealed that low hsa_circ_0036683 expression was a significant prognostic factor, independent from other clinicopathological features, for inferior RFS and OS. There was no significant association between the expression of these circRNAs and hepatitis B/C status or cirrhosis. This study therefore identified circRNAs as potential prognostic markers for patients who undergo curative surgery for HCC and highlighted hsa_circ_0036683 as the most useful biomarker.

DOI： 10.1038/s41598-021-85237-y

Web of Science

PubMed

　 PREV - NEXT 　

<KANDA Mitsuro>

Papers - KANDA Mitsuro